Vor Bio raises $55.6M in PIPE; extends cash runway to 2025 clinical data readouts

Vor Biopharma Inc.

Private placement of 55.87M shares and warrants for 69.84M shares at combined $0.99425 price, gross proceeds ~$55.6M.
New investor Reid Hoffman led; existing investor RA Capital participated; each gets one board seat and one observer seat.
Updated Phase 1/2 VCAR33 ALLO data expected H1 2025; Phase 1/2a trem-cel+Mylotarg data H2 2025.
Net proceeds to fund pipeline development and general corporate; warrant exercise could add $58.5M.
Warrants exercisable at $0.838/share, expire 7 years from issuance; closing expected Dec 30, 2024.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.